Newsroom

Sorted by: Latest

-

ABL Diagnostics : Cession d'un nouveau bloc d'actions par son actionnaire principal ABL

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD) informe que son actionnaire principal, Advanced Biological Laboratories (ABL), une société de diagnostic luxembourgeoise, a déposé, via ONDE, le dispositif centralisé de dépôt des informations auprès de l’Autorité des marchés financiers (AMF), une information relative à la cession d'un nouveau bloc d'actions ABL Diagnostics dans le cadre d'une opération de gré à gré avec un tiers privé. Le dépôt relatif à cette cessi...
-

Getlink SE: Information Relating to the Total Number of Shares and Voting Rights Which Form the Share Capital

PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE (Paris: GET) Presenter / Corporate Name : Getlink SE - Société Européenne, RCS Paris 483 385 142 37-39 rue de la Bienfaisance, 75008 Paris Date Number of ordinary shares in issue (1) Number of voting rights Theoretical (2) (3) Exercisable (4) 31 May 2026 550,000,000 642,868,087 635,364,950 * * * * (1) The share capital is divided into 550,000,000 ordinary shares of a nominal value of €0.40. (2) In accordance with Article 223-11 of the AMF Gene...
-

ABL Diagnostics: Sale of a new block of shares by its main shareholder ABL

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party. The filing relating to this sale can be viewed...
-

Getlink SE : Information relative au nombre total des droits de vote existants et d’actions composant le capital social

PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE (Paris: GET) Déclarant / Raison sociale : Getlink SE - Société Européenne, RCS Paris 483 385 142 37-39 rue de la Bienfaisance, 75008 Paris Date Nombre d’actions ordinaires composant le capital social (1) Nombre de droits de vote Théoriques (2) (3) Exerçables (4) 31 mai 2026 550 000 000 642 868 087 635 364 950 * * * * (1) Le capital social est divisé en 550 000 000 actions ordinaires d’une valeur nominale de 0,40 euro chacune. (2) Conformément...
-

Union calls for answers after Villa Marconi cuts hours, lays off cleaning staff ahead of Board elections

Ottawa, ON--(BUSINESS WIRE)--The union representing workers at Ottawa’s Villa Marconi Long - Term Care Centre held an information picket outside the home Friday morning, demanding answers after the management of the home issued layoff notices to five staff. The impacted staff, members of CUPE 4793 work in the Laundry and Environmental Services department. These workers ensure that clothing, bedding, and other linens are clean for the residents of the home. “We are still having issues with suppl...
-

Information relative au nombre total de droits de vote et d’actions Composant le capital social de la société emeis

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:EMEIS): Déclaration au 31 mai 2026   Nombre de titres composant le capital en circulation 161 440 050     Nombre total de droits de vote bruts* 184 264 973     Nombre total de droits de vote exerçables 183 631 723     * Les droits de vote bruts servent de base de calcul pour les franchissements de seuils : ils intègrent les droits de vote attachés aux actions privées de ce droit (auto-détention, contrat de liquidité etc.) voir note...
-

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, pres...
-

Feinstein Institutes’ John M. Kane honored with 2026 Schizophrenia International Research Society Lifetime Achievement Award

MANHASSET, N.Y.--(BUSINESS WIRE)--John M. Kane, MD, co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, was awarded the 2026 Lifetime Achievement Award from the Schizophrenia International Research Society (SIRS). This recognition celebrates his decades-long contributions that have transformed the understanding, treatment and outcomes for individuals living with schizophrenia worldwide. The SIRS Lifetime Achievement Award is one of...
-

Kontron Launches CERES-TSN Managed Time-Sensitive Networking Switch for Defense Applications

TOULON, France--(BUSINESS WIRE)--Kontron, a leading global provider of IoT/Embedded Computer Technology (ECT), announces the CERES-TSN, a compact, rugged, managed Ethernet switch designed for secure and reliable networking in mission-critical defense environments. It integrates time-sensitive networking (TSN), high bandwidth, and advanced security in a compact, fanless platform designed for embedded networks in ground defense systems and naval applications, with optional use in avionics. The sw...
-

ZimCal (BIMIZCI) Exposes Medallion Financial Corp.’s Latest Campaign of Distortion and the Risks of Re-Electing Its Unqualified Directors

MINNEAPOLIS--(BUSINESS WIRE)--ZimCal Asset Management through BIMIZCI Fund LLC responds (again) to Medallion Financial’s recent misleading press release designed to manipulate stockholders. Notably, BIMIZCI Fund LLC — not ZimCal or Mr. Hodges — is the nominating stockholder, a distinction Medallion deliberately blurs. Despite BIMIZCI Fund LLC being the nominating stockholder, Medallion (NASDAQ:MFIN) elected to lead with “Stephen Hodges and his affiliates” because their goals are clear. Use a se...